Efficacy of Dupilumab in Treating Atopic Dermatitis With Recurrent Eczema Herpeticum in a Patient With DOCK8-Deficiency Hyper-IgE Syndrome: A Case Report

Dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13, was used to successfully induce remission of chronic, disseminated eczema herpeticum in a six-year-old girl who has DOCK8-deficiency hyper-IgE syndrome. The patient was started on 200 mg of dupilumab administered once every...

Descripción completa

Detalles Bibliográficos
Autores principales: Johar, Reshale A, Hasanain, Afnan, Khouqeer, Yousef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494277/
https://www.ncbi.nlm.nih.gov/pubmed/37701007
http://dx.doi.org/10.7759/cureus.43360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494277/
https://www.ncbi.nlm.nih.gov/pubmed/37701007
http://dx.doi.org/10.7759/cureus.43360

Ejemplares similares